The Manufacturers Life Insurance Company Sells 72,548 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

The Manufacturers Life Insurance Company cut its stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 54.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 60,665 shares of the company’s stock after selling 72,548 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Taysha Gene Therapies were worth $122,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of TSHA. Creative Planning bought a new position in Taysha Gene Therapies in the 3rd quarter valued at $28,000. Principal Financial Group Inc. bought a new position in shares of Taysha Gene Therapies during the 2nd quarter worth $48,000. China Universal Asset Management Co. Ltd. increased its holdings in Taysha Gene Therapies by 79.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock valued at $79,000 after buying an additional 17,446 shares during the period. Intech Investment Management LLC bought a new position in Taysha Gene Therapies in the third quarter worth approximately $85,000. Finally, Scientech Research LLC purchased a new stake in Taysha Gene Therapies during the second quarter worth $97,000. 77.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on TSHA shares. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Canaccord Genuity Group upped their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, November 14th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ:TSHA opened at $2.01 on Tuesday. The business’s 50 day moving average price is $2.15 and its 200-day moving average price is $2.34. The firm has a market capitalization of $411.93 million, a PE ratio of 3.19 and a beta of 0.79. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. Taysha Gene Therapies, Inc. has a 1 year low of $1.19 and a 1 year high of $4.32.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.